Eurasian Journal of Chemical, Medicinal and Petroleum Research

Abstract This study conducts a cost-effectiveness analysis (CEA) of pharmaceuticals utilized in intensive care units (ICUs) across hospitals. The objective is to assess the economic viability of commonly prescribed drugs in critical care settings, considering both their therapeutic efficacy and financial implications. Data were gathered from ICU patients, including drug consumption, treatment outcomes, and associated costs. The analysis involved calculating the incremental cost-effectiveness ratio (ICER) for each drug, comparing it with standard treatment protocols. Results indicate a significant variance in cost-effectiveness among the drugs, with certain therapies providing optimal clinical outcomes at lower costs. The findings suggest that strategic drug selection based on cost-effectiveness could optimize resource allocation in ICUs, improving patient outcomes while minimizing expenditures. This research highlights the importance of integrating economic evaluation into clinical decision-making in critical care environments.

Abstract This study reviews management accounting systems (MAS) in hospitals and investigates their impact on optimizing pharmaceutical costs. Given the increasing pressure on healthcare institutions to control rising costs while maintaining high standards of care, understanding the role of MAS in managing drug-related expenses is crucial. The research examines how various accounting systems, including activity-based costing (ABC) and standard costing, are implemented in hospitals to track and allocate pharmaceutical expenditures efficiently. The analysis highlights the influence of these systems on decision-making processes related to drug procurement, inventory management, and the prescription practices of medical staff. Furthermore, the study explores how the optimization of pharmaceutical costs through effective MAS contributes to overall hospital financial sustainability and better resource utilization. The findings suggest that hospitals with robust management accounting systems are more likely to optimize drug-related costs, ultimately enhancing both economic and clinical outcomes.

Key terms: Management accounting systems, Pharmaceutical costs, Activity-based costing, Healthcare finance.

Abstract Pharmaceutical procurement and budgeting are critical aspects of financial management in hospitals, directly influencing their ability to provide quality care while controlling costs. Rising drug prices, regulatory challenges, supply chain disruptions, and inefficient procurement practices present significant hurdles for hospital administrators. Efficient management of pharmaceutical expenditures is vital not only for the financial sustainability of healthcare institutions but also for ensuring that essential medications are available to patients in a timely and cost-effective manner. This paper examines the challenges faced by hospitals in pharmaceutical procurement and budgeting, with a focus on rising drug costs, regulatory compliance, and supply chain vulnerabilities. It also discusses strategies that can be employed to optimize pharmaceutical purchasing, such as centralized procurement systems, bulk purchasing agreements, technology integration, evidence-based decision-making, and the promotion of generics and biosimilars. By adopting these strategies, hospitals can better manage their pharmaceutical budgets, ensure access to necessary medications, and maintain financial stability. This study provides insights into how hospitals can balance cost-control measures with high-quality care, ultimately leading to more efficient and sustainable healthcare systems.